Kaiser Health News: Old Drug Turned ‘Cash Cow’ as Company Pumped Price to $40K a Vial, Emails Show
Washington,
October 2, 2020
He argued that Mallinckrodt had invested $660 million in improving manufacturing of the drug and in seeking evidence that Acthar works for many other uses that the FDA permits. |